View Older Stories View More Recent Stories

May 29, 2018 09:20AM Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market
May 29, 2018 09:20AM Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market
May 24, 2018 08:56AM Fibrocell Science (FCSC) Announces 1-for-5 Reverse Stock Split
May 24, 2018 08:56AM Fibrocell Announces One-for-Five Reverse Stock Split
May 24, 2018 08:56AM Fibrocell Announces One-for-Five Reverse Stock Split
May 21, 2018 07:01AM Fibrocell Science (FCSC) Announces Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy
May 21, 2018 07:00AM Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
May 21, 2018 07:00AM Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
May 16, 2018 04:05PM Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology Meeting
May 16, 2018 04:05PM Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology Meeting
May 10, 2018 04:05PM Intrexon Announces First Quarter 2018 Financial Results
May 10, 2018 08:00AM Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights
May 10, 2018 08:00AM Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights
May 3, 2018 08:00AM Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent Highlights
May 3, 2018 08:00AM Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent Highlights
Apr 18, 2018 08:29AM Fibrocell Announces Review of Strategic Alternatives
Apr 18, 2018 08:01AM Fibrocell Science (FCSC) to Review Strategic Alternatives
Apr 18, 2018 08:00AM Fibrocell Announces Review of Strategic Alternatives
Apr 18, 2018 08:00AM Fibrocell Announces Review of Strategic Alternatives
Apr 10, 2018 08:00AM Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA
Apr 10, 2018 08:00AM Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA
Mar 19, 2018 08:00AM Fibrocell Reports 2017 Financial Results and Recent Highlights
Mar 19, 2018 08:00AM Fibrocell Reports 2017 Financial Results and Recent Highlights
Mar 12, 2018 08:00AM Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent Highlights
Mar 12, 2018 08:00AM Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent Highlights
Mar 6, 2018 08:04AM Fibrocell Science (FCSC) Announces FDA Allowance of IND for FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
Mar 6, 2018 08:00AM Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
Mar 6, 2018 08:00AM Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
Mar 1, 2018 04:05PM Intrexon Announces Fourth Quarter and Full Year 2017 Financial Results
Feb 6, 2018 08:00AM Fibrocell to Present at 20th Annual BIO CEO & Investor Conference
Feb 6, 2018 08:00AM Fibrocell to Present at 20th Annual BIO CEO & Investor Conference
Feb 5, 2018 08:02AM Fibrocell Science (FCSC) Announces Submission of IND for FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
Feb 5, 2018 08:00AM Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
Feb 5, 2018 08:00AM Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
Jan 30, 2018 08:04AM Fibrocell Science (FCSC) Reports FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of RDEB
Jan 30, 2018 08:00AM Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Jan 30, 2018 08:00AM Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Jan 24, 2018 08:00AM Fibrocell to Present at Phacilitate Cell and Gene Therapy World 2018 
Jan 24, 2018 08:00AM Fibrocell to Present at Phacilitate Cell and Gene Therapy World 2018 
Dec 11, 2017 04:01PM Fibrocell Announces Closing of $10.5 Million Underwritten Public Offering
Dec 11, 2017 04:01PM Fibrocell Announces Closing of $10.5 Million Underwritten Public Offering
Dec 7, 2017 07:03AM Fibrocell Science (FCSC) Prices 13.64M Shares at $0.77 w/Warrants
Dec 7, 2017 07:00AM Fibrocell Announces Pricing of $10.5 Million Underwritten Public Offering
Dec 7, 2017 07:00AM Fibrocell Announces Pricing of $10.5 Million Underwritten Public Offering
Nov 13, 2017 08:00AM Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights
Nov 9, 2017 04:05PM Intrexon Announces Third Quarter 2017 Financial Results
Nov 6, 2017 08:00AM Fibrocell to Host Conference Call and Webcast on Monday, November 13, 2017 to Discuss Third Quarter 2017 Financial Results and Recent Operational Highlights
Oct 2, 2017 04:30PM Fibrocell to Present at 2017 Cell & Gene Meeting on the Mesa
Sep 26, 2017 08:03AM Fibrocell Science (FCSC) Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for RDEB
Sep 26, 2017 08:00AM Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
View More Recent Stories View Older Stories